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Abstract Vesicoureteral reflux (VUR) in children is asso-
ciated with increased risk of urinary tract infection (UTI).
Recurrent UTI in the presence of the VUR is believed to
cause renal scarring, which carries a risk of subsequent hy-
pertension, toxemia of pregnancy, and significant renal
damage, including end-stage renal disease. The natural his-
tory of VUR is to improve or resolve completely with time in
most of the patients. The traditional management consists of
prompt treatment of UTI, long-term anti-microbial prophy-
laxis until the VUR resolves, or surgical intervention in those
with persistent high grade VUR, recurrent UTI in spite of
prophylaxis with anti-microbial agent, allergy to anti-
microbial agents, and patient/parent non-compliance with
the medical management. Voiding dysfunction and consti-
pation play an important role, and their diagnosis and
appropriate management helps reduce the frequency of UTI
and promote the resolution of the VUR. Patients with renal
scarring need to be monitored for potential complications
such as hypertension, proteinuria, and progression of the
renal damage. In patients with hypertension and/or protein-
uria, angiotensin-converting enzyme inhibitors (ACEIs) or
angiotensin II receptor blockers (ARBs) are the drugs of
choice, because of their reno-protective properties. Recent
studies have revealed that there is no convincing evidence
that UTI in the presence of VUR predicts renal injury or that
the use of long-term anti-microbial prophylaxis or surgical
intervention prevents renal scarring or its progression.
However, until proven otherwise by a prospective, placebo-
controlled, randomized study, it is advisable to err on the side
of caution and consider VUR and UTI risk factors for renal
scarring and treat each patient on individual basis.
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Introduction
Primary vesicoureteric reflux (VUR) is the most common
urological abnormality in children, with a prevalence of
approximately 1% [1]. It may be an isolated finding, or it
may occur in association with other anatomic renal ab-
normalities, such as multi-cystic dysplastic kidney, renal
agenesis, or ureteral ectopia. In a significant number of
cases, it is diagnosed after urinary tract infection (UTI).
According to the various reports, it is present in 8%–50%
of children, predominantly girls, with febrile UTI [2–4].
Many newborn babies are diagnosed with VUR during
follow-up for antenatally diagnosed hydronephrosis (ante-
natal VUR). Approximately 10% of fetuses with renal pelvic
diameter of greater than 5 mm at or beyond 28 weeks of
gestation are found to have VUR during examination after
birth [5]. Antenatal VUR, which is more common in boys,
is usually low grade, and the possibility of resolution is high
[5, 6]. Some cases of VUR are also diagnosed during family
screening of a known sibling or a parent with VUR; the
incidence of VUR in such cases is approximately 30% [7].
VUR predisposes to UTI, and the two are associated with
renal scarring (reflux nephropathy), which carries a risk of
subsequent hypertension, toxemia of pregnancy, and signif-
icant renal damage, including end-stage renal disease.
According to the North American Pediatric Renal Transplant
Cooperative Study (NAPRTCS) annual report of 2006, 536
(8.4%) of the 6,405 children with chronic renal insufficiency
had reflux nephropathy, which, according to the registry, is
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the fourth commonest cause of chronic renal insufficiency
after obstructive uropathy, renal aplasia/hypoplasia/dyspla-
sia, and focal segmental glomerulosclerosis (FSGS) [8].
The natural course of VUR is spontaneous resolution in
25% to 80% of cases, and it depends on the severity of
VUR and the duration of follow-up. Resolution may be
delayed by recurrent UTI, voiding dysfunction, and chronic
constipation [9, 10].Various treatment strategies have been
used in children with VUR, with the ultimate objective of
preventing renal injury. The two main treatment modalities
are long-term anti-microbial prophylaxis and surgical
correction. Since the natural tendency of the VUR is to
improve with time, medical management is generally
tailored to cover the period during which the VUR is likely
to cause the renal damage.
Natural history of VUR
The Birmingham Reflux Study, which interpreted negative
findings in a single voiding cysto-urethrogram (VCUG) as
the resolution of VUR, reported an approximately 50%
cessation of VUR after a 5-year follow up in medically
managed moderate-to-severe VUR [11]. In the International
Reflux Study in Children, which used the negative findings
of two consecutive VCUG examinations to confirm
resolution of VUR, the corresponding number was 25%
[12]. The rate of resolution is better in undilated ureters than
in dilated ureters, and in low-grade VUR than in high-grade
VUR. The International Reflux Study in Children reported
that VUR disappeared in more than 80% of undilated ureters
and in about 40% of dilated ureters [2]. Schwab et al.
reported that grades I–III VUR resolved at the rate of 13%
per year for the first 5 years of follow-up and 3.5% per year
during subsequent years. Grades IV and V VUR resolved at
the rate of 5% per year [13]. Some studies have also reported
that the cessation of VUR occurs sooner in children with
unilateral VUR than in those with bilateral VUR [12, 14].
Resolution of VUR occurs sooner in African–Americans.
In a study on black children, the mean duration to spon-
taneous resolution was 14.6 months, which was significant-
ly shorter than the 21.4 months in white children. No
significant difference was seen in the rate of spontaneous
resolution [15]. In newborn babies with VUR diagnosed
after abnormal findings in prenatal renal ultrasound (US)
(prenatal VUR), 67% of severe VUR and 78% of mild or
moderate VUR had resolved by the age of 2 years [16].
After a systematic review of published literature on the
resolution of VUR, Elder and colleagues reported that
increasing age at presentation and the presence of bilateral
VUR decrease probability of resolution and that bilateral
grade IV VUR has a particularly low chance of spontane-
ous resolution [17].
Medical management versus surgical management
Surgical correction of VUR was common until the concept
of anti-microbial prophylaxis for childhood UTI was
introduced in 1975 [18]. Numerous subsequent studies
revealed that medical management of VUR is as effective
as surgical treatment and that there is no significant
outcome difference between the two treatment modalities.
In the International Reflux Study Group in Europe, 287
children with severe VUR were randomly allocated to
medical (n=147) or surgical (n=140) groups. Follow-up
with di-mercaptosuccinic acid (DMSA) renal scans for a
period of 5 years revealed no difference in outcome
between children managed surgically or medically [19].
In the International Reflux Study in Children (IRSC),
which included 306 patients, no significant difference in
outcome was found between medical or surgical manage-
ment in terms of the development of new renal lesions or
the progression of established renal scars [20]. Similar
results were reported by the Birmingham Study [11]. In its
final report, the IRSC compared long-term outcome of med-
ical management versus surgical management in 252 children
less than 11 years old with non-obstructed grade III/IV VUR,
history of UTI, and a glomerular filtration rate (GFR) of
>70 ml/min per 1.73 m2 body surface area. The follow-up
period was 10 years. UTI recurrences and renal growth were
similar in the two groups, but the medically treated group
had more febrile infections. The report concluded that, with
close supervision and prompt treatment of UTI recurrence,
children in medical or surgical groups did equally well [21].
Medical management seems appropriate for VUR
grades I–III unless the patient has recurrent breakthrough
UTI, is allergic to the anti-microbial agents, or has
compliance issues. For VUR grade IV, the choice of medical
management versus surgical management is controversial.
The spontaneous resolution rate is <40% after 5-year follow
up. Decision for surgical intervention depends on the
patient’s age, renal function, duration of follow-up, and
other factors as for those with VUR grades I–III. VUR
grade V has the lowest rate of spontaneous resolution,
particularly in older children, and some advise surgical
intervention if there is no improvement within a year—
certainly if the patient has recurrent infections while on anti-
microbial prophylaxis [12, 22, 23].
Anti-microbial prophylaxis
The medical management of VUR consists primarily of
long-term anti-microbial prophylaxis. This approach is
endorsed by many professional societies, which include
the American Academy of Pediatrics [24], the Swedish
Medical Research Council [25], and the American Uro-
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logical Association [17]. Anti-microbial agents most appro-
priate for prophylaxis include trimethoprim-sulfamethoxa-
zole (TMP-SMZ), trimethoprim alone, nitrofurantoin, or
cephalexin [24, 26]. According to one report, nitrofurantoin
is more effective than TMP-SMZ as a prophylactic agent
[27]. In view of an increasing resistance of E. coli,
ampicillin and amoxicillin are less effective as prophylactic
agents [24, 28, 29] and are not used for this purpose beyond
the first 2 months of the child’s life, during which period it
is advisable to avoid TMP-SMZ. In toilet-trained children,
the medication is generally administered at bed time,
though this recommendation is not evidence based.
The prophylactic dose of anti-microbials is one-fourth to
one-half of the therapeutic dose for acute infection. The
dosage for commonly used anti-microbials is as follows
[24, 26]:
TMP-SMZ TMP 2 mg per kg as a single dose, or
5 mg of TMP per kg twice per week
Nitrofurantoin 1–2 mg/kg as a single daily dose
Cephalexin 10 mg/kg as a single daily dose
Ampicillin 20 mg/kg as a single daily dose
Amoxicillin 10 mg/kg, as a single daily dose
In 1997, the American Urologic Association (AUA) pub-
lished its guidelines on the management of VUR in children.
The recommendations were based on a systematic review
that involved 168 articles on VUR that were published from
1965 to 1994. The seven treatment modalities that were
studied included (1) intermittent antibiotic therapy, (2)
bladder training, (3) continuous antibiotic prophylaxis, (4)
antibiotic prophylaxis and bladder training, (5) antibiotic
prophylaxis, anti-cholinergics and bladder training, (6) open
surgical repair, (7) endoscopic repair. The key outcome
measures were: resolution of VUR, risk of pyelonephritis
and scarring, and complications of medical management
versus surgical management. The study panel recommended
antibiotic prophylaxis for all grades of VUR in children less
than a year of age because of a very high rate of spontaneous
resolution. For children 1–5 years old, antibiotic prophylaxis
is recommended for all grades of VUR, with surgical options
in grades III to V if VUR is bilateral or renal scarring is
present. For children older than 6 years antibiotic prophy-
laxis is recommended for grades I and II (unilateral or
bilateral) and unilateral grades III and IV, with surgical
options if renal scarring is present; and surgical repair for
bilateral grade III and IV, and unilateral or bilateral grade V
VUR with or without scarring since the VUR has the least
possibility of spontaneous resolution [17].
The duration of anti-microbial prophylaxis and the
potential need for surgical intervention depends on the age
of the patient, the severity of the VUR, frequency of UTI,
and the degree of renal scarring, if present. Some rec-
ommend cessation of anti-microbial prophylaxis after the
ages of 5–7 years, even if low-grade VUR persists [30].
The Swedish Medical Research Council published its
recommendations in 1999, which recommended no anti-
microbial prophylaxis for VUR grades I and II at first
examination. For those with VUR grades III and IV on first
examination, anti-microbial prophylaxis for 1 year is
recommended, at which time it should be discontinued if
the VUR grade has decreased to grades 0–II. If there is no
change in the VUR grade, and the patient is a boy, the
prophylaxis can be discontinued, whereas its continuation
of prophylaxis or surgical intervention is recommended for
such girls. For grade V VUR at all ages and bilateral
grade IV in children less than a year old on the first
examination, the panel recommended that anti-microbial
prophylaxis should be started, the management should be
individualized, and surgical intervention may be considered
if there is no change in VUR after 1 year. The importance
of bladder function evaluation and hygiene, and a careful
follow-up of patients, including DMSA renal scan, was
emphasized [25].
Follow-up of patients with VUR and UTI requires close
monitoring for the early detection and prompt treatment of
UTI, changing of anti-microbial prophylaxis if the patient
has recurrent breakthrough UTI , and the monitoring of the
VUR by periodic VCUG examinations. The timing for
follow-up VCUG is not well-defined, though most practi-
tioners do it yearly. In an effort to estimate the optimum
timing for follow-up VCUG examinations, Thompson et al.
derived a decision-tree model from the published data on
VUR and validated the model by using a retrospective
cohort of 76 patients. The authors concluded that delaying
the VCUG from yearly to every 2 years in children with
mild VUR (grades I and II) and every 3 years in children
with moderate/severe VUR (grades III or higher) yields
substantial reductions in the average numbers of VCUG
examinations and costs, with a modest increase in anti-
microbial exposure [31].
Limitations of anti-microbial prophylaxis Long-term anti-
microbial prophylaxis has its limitations. It is not always
effective: the breakthrough UTI rates in children with VUR
range from 25%–38% [11, 12]. Anti-microbial resistance is
a major concern with long-term anti-microbial prophylaxis.
In one study, children who had received the medication for
more than 4 weeks in the preceding 6 months had more
resistant E. coli than did those not on such treatment [odds
ratio (OR) = 13.9; 95% confidence interval (CI) 8.2–23.5]
[32]. In another study on childhood UTI, a generalized
decrease in bacterial susceptibility to common antibiotics
was seen in 1999 when compared with those previously
seen in 1991 [32]. Approximately 10% of children on long-
term prophylaxis have adverse reactions, most of which
occur within the first 6 months. These include gastrointes-
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tinal symptoms, skin rashes, hepatotoxicity, and hemato-
logical complications with SMZ-TMP, and mostly gastro-
intestinal symptoms with nitrofurantoin. More severe adverse
reactions, such as marrow suppression, and, rarely, Stevens–
Johnson syndrome, may also occur with SMZ-TMP [33, 34].
Compliance with daily administration of the medication
over a prolonged period of time is questionable. In one
study, 97% of the parents reported compliance with low-
dose daily anti-microbial prophylaxis, and yet the medicine
was found in only 31% of the patients’ urine [35]. Other
concerns with long-term anti-microbial prophylaxis are the
inconvenience to patients with repeated follow-up VCUG
examinations to monitor the VUR resolution, and the cost of
the procedure.
Controversies over anti-microbial prophylaxis Many stud-
ies have raised serious doubts about the efficacy of long-
term anti-microbial prophylaxis in the prevention of renal
injury in patients with VUR. Shindo et al. observed that
renal scarring, the injury presumably having been initiated
by VUR, can progress despite correction of the reflux and
prevention of UTI [36]. Arant et al. reported that, in spite of
good medical management, even mild and moderate VUR
can be associated with renal injury [37]. In a study on 51
children (mean age 8.6 years) with VUR (grades I–IV), the
prophylactic antibiotic was discontinued after a mean period
of 4.8 years. After a mean follow-up period of 3.7 years, only
11.8% patients had UTI, and no new scars had developed in
any of the patients [30]. Other reports that raise doubts
about the usefulness of long-term anti-microbial prophy-
laxis include the observation that up to half of patents with
severe VUR exhibit no evidence of renal damage [38],
incidence of renal scars does not always match the severity
of VUR [39], and the frequency of pyelonephritis is similar
with or without the resolution of VUR [12]. In a ran-
domized study involving 113 children with grade I–III
VUR in the age group of 3 months to 12 years, Garin et al.
reported no difference in recurrence rate of UTI and renal
scarring at 1 year between those who received prophylaxis
and those who did not [40].
In a systematic analysis that compared antibiotics with
placebo or no treatment for preventing UTI in susceptible
children, Williams and colleagues concluded that most
published studies to date have been poorly designed, with
biases known to overestimate the true treatment effect [41].
Another systematic analysis, which evaluated the value of
identification of VUR after symptomatic UTI and the
effects of various interventions on the occurrence of UTI
and subsequent renal parenchymal damage, concluded that
it is uncertain whether the identification and treatment of
children with VUR confers clinically important benefit and
whether any intervention, including antibiotic prophylaxis
or surgery for VUR, is better than no treatment [42].
In view of a lack of consensus over the management of
VUR and increasing doubts about the relevance of long-
term anti-microbial prophylaxis in preventing renal dam-
age, the National Institutes of Health (NIH)/National
Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) has initiated a multicenter, prospective, random-
ized, placebo-controlled study that will investigate the role
of anti-microbial prophylaxis in preventing recurrent UTI
and renal scarring in patients with VUR. This study will
include children aged 2 months to 5 years with grades I–IV
VUR with first UTI.
Voiding dysfunction and VUR
VUR may be associated with voiding dysfunction, which, in
some cases, may present as dysfunctional elimination syn-
drome (DES). The symptoms of DES include daytime wet-
ness, urgency, frequency, infrequency, constipation or fecal
incontinence in “toilet trained” children, with no underlying
anatomic or neurological abnormality [43–45]. The exact
pathogenesis of voiding dysfunction or DES is not known. It
seems to be an abnormally learned spectrum of voiding,
which evolves from poorly learned voiding technique and
attempts to suppress impending or active bladder contrac-
tions by inappropriately contracting the pelvic floor muscles
and tightening the sphincter [44, 46]. This results in in-
creased voiding pressure and/or inefficient voiding [47, 48].
Voiding dysfunction predisposes to recurrent UTI, in-
duces and perpetuates VUR, and may result in permanent
renal damage [9, 10]. In a study by Koff et al. DES, besides
increasing the rate of breakthrough UTI, it delayed reso-
lution of VUR that was 1 grade less severe by an average of
1.6 years. DES also adversely affected the results of ureteric
re-implantation [45]. In another study that involved the use
of a questionnaire in 310 children enrolled in the European
branch of the International Reflux Study in Children, a
strong negative correlation was seen between recurrences of
urinary tract infections, as well as disappearance of VUR
and non-neuropathic bladder/sphincter dysfunction [49].
Voiding dysfunction or DES is a diagnosis of exclusion
that mandates the taking of a detailed history and a physical
examination to rule out any underlying neurological or
neuromuscular etiology. The diagnosis is usually evident
clinically, and urinalysis, bladder ultrasound, and VCUG in
selected cases are helpful in making a diagnosis. The role of
urodynamic studies is not well established, partly because
the study result is not consistent [44, 50, 51]. The procedure
is invasive, and the study result does not change therapy or
influence the final outcome. A thorough history taking and
physical examination lead to the correct diagnosis and
treatment in the majority of children [52].
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The treatment of voiding dysfunction or DES may in-
clude the use of laxatives and timed frequent voiding every
2 to 3 hours. Pelvic floor exercises, behavioral modifica-
tion, and/or anti-cholinergic medication may be required. A
combination of conservative medical and computer game-
assisted pelvic floor muscle retraining decreased the
incidence of breakthrough UTI and facilitated VUR reso-
lution in children with voiding dysfunction and VUR [53].
Similar results of improved outcome with medical manage-
ment have been reported by others [54, 55].
Constipation and VUR
Besides being a part of dysfunctional elimination syn-
drome, constipation may be an isolated finding, which by
itself increases the risk of recurrent UTI or voiding dys-
function in children with VUR. This is believed to result
from compression of the bladder and bladder neck that in-
creases bladder storage pressure and post-void residual urine
volume. Also, a distended colon and/or soiling provide an
abundant reservoir of pathogens [56–58]. Constipation in
children increases the likelihood of urinary incontinence,
bladder overactivity, discoordinate voiding, a large capacity
and poorly emptying bladder, recurrent UTI, and deteriora-
tion of VUR [59]. In a study that involved 366 children,
constipation/encopresis was reported in 30% of cases, day-
time wetting in 89%, night wetting in 79%, and recurrent
UTI in 60% of the patients. VUR was present in 20% of the
patients who underwent cysto-urethrography. Multi-disciplinary
management helped the resolution of VUR in 53% of the
patients, after a mean follow-up period of 22 months [55].
Treatment of constipation by dietary measures, behav-
ioral therapy, and laxatives helps reduce UTI recurrence
and the resolution of enuresis and uninhibited bladder
contractions [57, 60].
VUR and renal scarring
Many children with VUR have renal scars at the time of
diagnosis or develop new scars during the follow-up. In a
study involving 127 adults (mean age 41 years) with VUR
diagnosed during childhood, 44 (35%) had unilateral renal
scarring, 30 (24%) had bilateral renal scarring, 12 (9%) had
proteinuria, 30 (24%) had albuminuria, and 14 (11%)
patients had hypertension. Of the 30 patients with bilateral
renal scars, 25 (83%) had an abnormal GFR [61]. Another
study on 21 adults (mean age 23.9 years, range 16–37 years)
with gross VUR diagnosed in infancy revealed that three
(23%) of the 13 patients with unilateral reflux nephropathy
and two (50%) of the four patients with bilateral reflux
nephropathy had proteinuria and renal insufficiency [62]. A
high incidence of micro-albuminuria has also been reported in
children with pyelonephritic renal scarring. A study involving
57 such children (1–17 years old) revealed significantly lower
GFR (median 93 ml/min per 1.73 m2 vs 111 ml/min per
1.73 m2 in controls) and higher urine albumin excretion
(median 20 μg/min per 100 ml GFR vs 9.2 μg/min per
100 ml GFR in controls). An inverse correlation was found
between urine albumin excretion and GFR. Increased urine
albumin excretion (>20 μg/min per 100 ml GFR) was found
in 51% of the children with pyelonephritic scarring; only
14% had increased serum creatinine [63].
The predisposing factors for renal scarring include
younger age, presence of urological abnormality, and recur-
rent UTI [2, 64, 65]. The follow-up of children with renal
scarring, with or without the resolution of VUR, is im-
portant because of a higher risk of hypertension, protein-
uria, and the progression of the renal disease [62, 63, 66,
67]. These complications are attributed to hyperfiltration in
the remnant glomeruli following renal parenchymal loss,
which leads to the development of glomerulosclerosis, acti-
vation of the renin–angiotensin system, and a gradual dete-
rioration of renal function [68, 69] Studies have indicated
that the mesangial alterations occur early in the course of
reflux nephropathy, even before proteinuria is detectable by
routine analysis; the other extreme is the occurrence of
focal segmental glomerulosclerosis (FSGS) with clinically
significant proteinuria and nephrotic syndrome [70].
The exact cause of hypertension due to renal scarring is
not known, but it is believed to be due to segmental ischemia
with increased renin secretion, and it does not depend on the
severity of the scarring [71–73]. Of the 306 patients entered
into the IRSC, three had hypertension at study entry. Of the
three, two became normotensive within 5 years of follow-
up and the third one required anti-hypertensive medication
at the end of the study. Three more patients became hy-
pertensive during follow-up [21]. In another study involv-
ing 664 patients diagnosed with VUR between 1970 and
2004, 20 (3%) developed hypertension. The estimated
probability of hypertension was 2% (95%CI 0.5–3%), 6%
(95%CI 2–10%), 15% (95%CI 11–20%) at 10 years,
15 years, and 21 years of age, respectively. The survival
analysis revealed that approximately 50% of children with
unilateral and bilateral renal damage had developed
persistent hypertension at about 30 years and 22 years of
age, respectively. The presence of hypertension strongly
correlated with the renal damage at entry [67].
Appropriate management of hypertension and/or pro-
teinuria is important to slow down the progression of the
renal disease. Even though there is a large number of
available anti-hypertensive drugs, the angiotensin-converting
enzyme inhibitors (ACEIs) or angiotensin II receptor
blockers (ARBs) are the preferred ones because of their
renoprotective effect. Studies have revealed that ACEIs, in
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addition to lowering the blood pressure, reduce proteinuria
due to reflux nephropathy [74] A combination of ACEIs
and ARBs significantly improves the renoprotective effects
of ACEIs [75]. However, it is not known whether this anti-
proteinuric effect slows down the progression of the renal
disease. In some patients with one very poorly functioning
scarred kidney and a healthy other kidney, the removal of a
poorly functioning kidney may help cure hypertension [76].
Conclusion
Serious doubts exist about the role of long-term anti-
microbial prophylaxis in preventing renal injury in children
with VUR. This is because the current recommendations
are based on non-randomized studies that were small in
size, were not placebo controlled and that included patients
with pre-existing renal damage that was diagnosed after the
onset of UTI. Systematic reviews of the published literature
on the subject have highlighted these shortcomings.
However, until the results of an appropriately designed,
placebo-controlled, prospective study become available, the
prudent thing to do is to assume that VUR is a risk factor
for renal scarring and treat each patient on an individual
basis, with due attention being paid to voiding dysfunction,
constipation, and renal scarring, if present.
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Multiple choice questions
(Answers appear following the references)
1. Which ONE of the following is the appropriate anti-
hypertensive medication in a 9-year-old boy with right
reflux nephropathy and mild proteinuria with normal
blood chemistry?
A. Angiotensin-converting enzyme inhibitor
B. Calcium channel blocker
C. Hydrochlorothiazide
D. Beta blocker
2. Which ONE of the following is true of anti-microbial
prophylaxis in children with VUR?
A. The long-term renal outcome is better than that of
surgical intervention
B. Amoxicillin is the drug of choice in a 2-year-old
patient
C. There is no convincing evidence that it is better
than a placebo in preventing renal injury
D. About 10% of patients have adverse reactions
3. Which ONE of the following is true of renal injury in
VUR?
A. The incidence of renal scars always matches the
severity of VUR
B. Correction of VUR prevents renal scarring
C. Some patients with severe VUR have no renal scarring
D. Male patients are more susceptible than female
patients are
4. A 12-year-old girl is on a maximum dose of a calcium
channel blocker (CCB) and hydrochlorothiazide for
hypertension secondary to left reflux nephropathy. The
most recent VCUG showed grade II VUR on the left
side. A DMSA renal scan showed a differential GFR of
12% in the left kidney and 90% in the right kidney. An
echocardiogram 2 weeks ago revealed moderate left
ventricular hypertrophy. The patient’s compliance with
the medication is questionable. Of the following, which
ONE would be the most appropriate management for
this patient?
A. Deflux procedure
B. Emphasize the need for compliance withmedications
C. Left nephrectomy
D. Change CCB to an angiotensin-converting enzyme
inhibitor
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